HepaTx Corporation (YC S18)

A New Alternative To Liver Transplants

https://wefunder.com/hepatx

Total raised on Wefunder: 123161

Total investors: 69

Quick facts

  • Breakthrough therapeutic Hx-001 is designed to regenerate liver and reduces the need for transplants
  • Addressing $20B+ liver disease crisis affecting 1/5 adults, 70% cheaper than transplants
  • Preclinical studies show encouraging signs of reduced liver damage, inflammation, and fibrosis
  • Prestigious Mayo Clinic license agreement brings expertise to reduce manufacturing and clinical risk
  • Raising $1.2M to unlock manufacturing readiness and studies to enter human trials within 24 months
  • Proprietary ProteoTrack diagnostic system offers a future second revenue stream
  • Backed by YC and Stanford StartX, raised > $4.2M with ~$700K in grants
  • Deeply experienced biotech leadership and scientific advisors

Team profiles

Featured investor profiles

Invest in HepaTx Corporation (YC S18)

A New Alternative To Liver Transplants

$358,850

raised from 69+ investors
INVESTMENT TERMS
Future Equity
 $17.5M  $15M post-money valuation cap
Early Bird Bonus: The first $300K of investments will be in a SAFE with a $15M valuation cap

Highlights

VC-Backed

Raised $250K or more from a venture firm

VC-Backed

Y Combinator

Raised from Y Combinator

Y Combinator
1
Breakthrough therapeutic Hx-001 is designed to regenerate liver and reduces the need for transplants
2
Addressing $20B+ liver disease crisis affecting 1/5 adults, 70% cheaper than transplants
3
Preclinical studies show encouraging signs of reduced liver damage, inflammation, and fibrosis
4
Prestigious Mayo Clinic license agreement brings expertise to reduce manufacturing and clinical risk

Related company links

Featured Investors


Team


Pitch Deck

1 / —

What If Treating Liver Failure Did Not Require a Transplant?

THE FIRST SCALABLE REGENERATIVE THERAPY FOR LIVER FAILURE

For patients and families facing advanced liver disease, the need for more treatment options is deeply personal. Transplantation can save lives, but donor organs are scarce, and many patients are not eligible to receive one. HepaTx is pursuing a different possibility: helping a damaged liver recover rather than replacing it.

Our lead candidate, Hx-001, is an investigational cell therapy designed to reduce inflammation and support liver repair, beginning with alcohol-associated hepatitis. Using cells derived from donated fat tissue, we are developing a process for producing, preserving, and distributing therapeutic cells at scale.

The ambition is a treatment available when patients need it. The work today is to establish the manufacturing consistency and scientific evidence needed to advance into human testing.

This community round will help fund that next stage, turning promising research into the evidence needed to determine what Hx-001 could make possible for patients.

ADVANCING FROM THE LAB TOWARD HUMAN TRIALS

HepaTx is developing next-generation cell therapies for liver regeneration. Founded on an innovative new technology from Stanford University, we are focused on addressing severe liver injuries, including MASH, autoimmune hepatitis, alcohol-associated hepatitis, and acute-on-chronic liver failure with our lead flagship product, Hx-001.

Our proprietary platform enhances cell therapy potency, scalability, and economic viability.

Hx-001 is currently in preclinical development, before human testing. Under our license agreement with Mayo Clinic, we are advancing toward a planned Pre-IND submission in 2027, followed by an IND submission, and an initial study planned for 2028/2029.

This would mark a critical transition from laboratory research to evaluating safety and potential benefit in patients.

With a strong intellectual property portfolio and an experienced team, HepaTx aims to revolutionize liver disease treatment and meet a significant unmet medical need.

BACKED BY STAKEHOLDERS WHO KNOW HOW TO BRING NEW THERAPIES TO PATIENTS

HepaTx has brought together investors, industry collaborators, academic researchers, patient advocates, and scientific and clinical advisors to help turn promising research into a therapy that can reach patients.

That network connects capital with expertise in liver biology, cell manufacturing, and clinical development.

Our scientific advisors help guide the research, while clinicians bring experience treating the patients we ultimately hope to serve.

Patient advocates keep the challenges facing patients and families central to the mission.

Together, these relationships help us anticipate development hurdles, make informed decisions, and advance Hx-001 toward human testing.

HepaTx Network

Our Scientific Advisory Board

Our Clinical Advisory Board

THIS ROUND WILL BRING HX-001 CLOSER TO HUMAN TESTING

HepaTx is ready to turn years of research and development into the next critical evidence needed to bring Hx-001 to patients.

We are raising $1.2 million to advance Hx-001 through the next critical stage of preclinical development and preparation for human trials. Our goal is to file a Pre-Investigational New Drug (Pre-IND) application in 2027 and advance toward a Phase I clinical trial potentially starting in 2028/2029.

The funding will support three priorities:

  1. Manufacturing readiness: Refining the production process to support consistent, clinical-grade cell therapy manufacturing.
  2. IND-enabling studies: Advancing the preclinical testing and documentation needed to support a future FDA submission.
  3. Clinical preparation: Supporting the regulatory and operational work needed to move toward an initial human study.

LIVER DISEASE IS A MASSIVE HEALTHCARE CRISIS WITH TOO FEW TREATMENT OPTIONS

Over 30 million Americans suffer from liver disease. Of those, more than 1,000,000 people each year develop end-stage liver failure, and many will require an organ transplant to survive.

The fundamental issue in the system is that there are not enough donor livers to cover the demand for healthy transplants.

Despite the $8.5 billion spent annually on patient care and facilitating this procedure, only 1 in 10 receive the transplant that will save their life. A transplant that can cost nearly and has a 10% to 30% rejection possibility within the first 90 days. Unfortunately, in today's world, doctors really have no alternative to pharmaceutical disease management until it's time for a transplant. That's when those sobering numbers really kick in.

In this arena, those numbers are literally a matter of life or death.

Beyond the human cost, liver disease represents a global treatment market estimated at more than $20 billion annually. The combination of substantial unmet medical need and high treatment costs creates a significant opportunity for new therapeutic approaches.

We are no longer asking ourselves ‘Will we ever revolutionize liver disease treatment?’

HepaTx has dedicated our medical expertise, resources and undivided attention to discovering HOW we will revolutionize liver disease treatment. We are discovering HOW can we help people avoid a liver transplant and HOW can we make the cost of an alternative insignificant compared to a transplant.

HELPING THE LIVER REPAIR ITSELF INSTEAD OF REPLACING IT

At HepaTx, we are developing a revolutionary new approach to liver treatment. An administration of hepatocyte-like cells to stimulate the replacement of dead and diseased liver cells.

Instead of waiting years on a massive waiting list for a liver transplant that might never come, HepaTx takes a sample of ordinary fat tissue cells and literally retrains them to stimulate and direct liver repair. We then inject those new cells into the patient to naturally heal their damaged liver from the inside out. It potentially turns a complex, high-risk surgery into a scalable, off-the-shelf treatment that can save thousands of lives.

Liver disease can destroy the body’s ability to clean toxins, process nutrients, and stay alive — and for many patients, a transplant is the only option. HepaTx is developing therapies designed to help damaged livers recover and function again, potentially changing the future of treatment for millions of people.

HepaTx is creating regenerative therapies that aim to restore liver function by helping the body repair damaged tissue naturally. The goal is to provide a new option for patients with severe liver disease, addressing one of healthcare's largest unmet needs.

Using an investigational medicine technology called Hx-001, HepaTx is developing a new type of treatment, based on stem cells, to bring new therapy to patients with late stage liver disease, as an alternative to liver transplant.


Our proprietary technology, owned by HepaTx, is based on technology invented at Stanford and is well protected. It provides a potential alternative to costly transplants and can be implemented across many liver diseases.

Unlike therapies that rely on a limited supply of donor liver cells, Hx-001 is being developed using an abundant source of starting material. The cells can be manufactured in advance, preserved, and stored for future use. This creates the potential for an off-the-shelf treatment that does not need to be manufactured separately for each patient.

EARLY RESEARCH SHOWS PROMISING SIGNS OF LIVER REPAIR

HepaTx has demonstrated proof of concept for Hx-001 in preclinical studies, generating encouraging results in animal models of liver injury. In mouse studies, Hx-001 treatment was associated with:

  1. Reduced liver damage: Lower levels of biomarkers associated with liver injury.
  2. Reduced inflammation: Decreases in inflammatory markers that contribute to liver damage.
  3. Reduced fibrosis: Lower levels of markers associated with the formation of liver scar tissue.
  4. Signs of liver regeneration: Increased markers of liver cell proliferation and protection.


These findings support the potential of Hx-001 to address multiple aspects of liver injury through a single cell therapy.

The next critical step is determining whether these promising preclinical results can translate into safe and effective treatment for human patients.

MAKING LIVER REGENERATION COMMERCIALLY VIABLE AT SCALE

A promising therapy only changes healthcare if it can be produced reliably, delivered efficiently, and made economically accessible.

HepaTx has developed a proprietary manufacturing process designed to address these challenges. Using abundant donor-derived fat tissue, we can produce therapeutic cells through a controlled process that improves consistency and supports larger-scale production.

Unlike patient-specific cell therapies, Hx-001 is designed to be manufactured in advance, frozen, stored, and distributed for use when needed. This creates the potential for a more efficient manufacturing and delivery model.


We project that Hx-001 treatment could cost approximately 70% less than a liver transplant, creating significant potential savings for healthcare payers while supporting attractive commercial economics. We estimate approximately $790,000 in potential healthcare savings per transplant avoided, before accounting for the price of Hx-001.

This creates an opportunity for value-based pricing that could generate meaningful revenue for HepaTx while still delivering savings to healthcare payers.

SERVING MULTIPLE POTENTIAL THERAPIES AND MARKETS

Hx-001 is our first priority, but HepaTx's long-term opportunity extends well beyond a single treatment.

Our proprietary technology is designed to tailor the functions of therapeutic cells to address different diseases. This creates the potential to build a portfolio of treatments using the scientific expertise, intellectual property, and manufacturing capabilities developed through Hx-001.

Our broader therapeutic pipeline includes Hx-002, which combines therapeutic cells with biomaterials to develop longer-lasting implants for liver disease, and Hx-003, which explores genetically modified cells for autoimmune hepatitis.


A SECOND TECHNOLOGY CREATES LONG-TERM UPSIDE BEYOND OUR CORE THERAPY

While Hx-001 remains our primary development and investment priority, HepaTx is also developing ProteoTrack™, a complementary diagnostic technology designed to monitor the health and function of transplanted cells and organs.

By detecting changes in transplanted cell function, ProteoTrack could help clinicians identify potential problems earlier, when intervention may be more effective.

This represents an additional potential commercial opportunity without changing our near-term focus on advancing Hx-001 toward human trials.

EACH DEVELOPMENT MILESTONE BRINGS US CLOSER TO CLINICAL VALIDATION

Developing a new therapy requires progressing through a series of technical, regulatory, and clinical milestones. Each successful step generates evidence that can reduce uncertainty and support the next stage of development.

For HepaTx, the most important milestones ahead include completing manufacturing development and IND-enabling studies, obtaining regulatory clearance to begin human testing, and generating our first clinical data.

The transition from preclinical research to human testing represents a major potential value inflection point. Early clinical results could provide the evidence needed to attract additional investment, establish strategic development partnerships, or pursue other opportunities to advance Hx-001 toward commercialization.

Our long-term strategy is to build value through disciplined clinical development, with opportunities for strategic partnerships or acquisition as the technology advances.


HELP US BRING A NEW GENERATION OF LIVER THERAPIES TO PATIENTS

Years of research have brought HepaTx to an important stage. We are now working to translate that progress into clinical evidence and a clearer understanding of what Hx-001 could accomplish for patients.

Through this community round, we are inviting investors to participate in the next chapter of HepaTx's development and share in the potential value of what we are building.

Join us as we work to make liver regeneration a practical treatment option for patients who need it.


Technology FAQs

What exactly is Hx-001, and does it use the patient's own cells?

Hx-001 is an investigational, donor-derived (allogeneic) cell therapy designed to support liver repair and regeneration.

HepaTx starts with adult adipose-derived stromal cells obtained from donated fat tissue and uses a proprietary approximately 12-day process to produce liver tissue repair cells with hepatocyte-like properties.

Unlike therapies manufactured individually for each patient, Hx-001 is designed to be produced in batches, frozen, stored, and made available as an off-the-shelf treatment.


How is HepaTx different from earlier stem-cell and tissue-engineering approaches?

Previous regenerative medicine programs have encountered challenges involving consistent therapeutic activity, cell sourcing, complex manufacturing, and translating promising research into effective human treatments.

HepaTx has designed Hx-001 to address several of these challenges through standardized, off-the-shelf manufacturing, cryopreservation, proprietary cell preconditioning, and a focused initial clinical indication.

These are important design distinctions, although human safety, efficacy, and commercial viability remain to be demonstrated.


What scientific evidence supports Hx-001, and has the research been independently validated?

HepaTx has evaluated Hx-001 in four animal models addressing different forms of liver injury and disease, alongside human-derived laboratory systems, including a 3D MASH model.

Across these studies, the company reports reductions in liver injury and inflammatory markers, improvements in fibrosis-associated measures, and indications of hepatocyte protection and regenerative activity.

Research involving HepaTx-supplied cells has been conducted by groups at the University of Louisville, Nanyang Technological University, and the National University of Singapore. The underlying cell-differentiation technology originated at Stanford and has been described in peer-reviewed research.

These results provide encouraging preclinical support, but Hx-001 has not yet demonstrated safety or efficacy in human patients.


What are the biggest remaining risks before Hx-001 can become an approved therapy?

The central challenge is demonstrating that the biological effects observed in preclinical studies translate into meaningful benefits for human patients.

Other important risks include treatment safety, immune responses, dose selection, consistency of manufacturing, and regulatory requirements.

HepaTx has sought to reduce uncertainty by evaluating Hx-001 across multiple disease models and human-derived laboratory systems. Its upcoming manufacturing, regulatory, and clinical milestones are intended to address additional questions.

However, the outcome of human trials remains uncertain, and regulatory approval is not guaranteed.

Can Hx-001 actually be manufactured and distributed at commercial scale?

Hx-001 uses a donor-derived manufacturing approach designed to support consistent, repeatable production.

One liter of donor adipose tissue can support cell-bank expansion sufficient for hundreds of potential patient doses.

The results of international research shipments of cryopreserved cells point to post-thaw viability above 90% and retained measured biological activity.

These are promising indicators of manufacturability and logistical feasibility. Further work is required to establish validated clinical-grade production, commercial-scale economics, and regulatory compliance.


Why is HepaTx initially targeting severe alcohol-associated hepatitis?

Severe alcohol-associated hepatitis can be life-threatening, particularly among patients who do not respond to corticosteroids or are unable to receive them.

This provides a defined patient population with substantial unmet medical need and a focused opportunity to evaluate Hx-001's safety and potential therapeutic benefit.

The strategy also allows HepaTx to concentrate its initial development resources rather than pursuing multiple indications simultaneously.

Successful clinical development could support expansion into additional liver diseases, such as autoimmune hepatitis, although each would require appropriate evidence and regulatory development.

Commercial FAQs

How large is the commercial opportunity, and how would HepaTx generate revenue?

Liver disease represents a substantial global healthcare burden, with a treatment market estimated at more than $20 billion annually.

If approved, Hx-001 could generate revenue through sales of its cell therapy, potentially supported by commercial partnerships for manufacturing, distribution, or market access.

The company's longer-term opportunity includes additional liver disease indications and other products developed from its cell therapy platform.


How does HepaTx compare with other companies developing regenerative therapies for liver disease?

HepaTx's differentiation centers on its proprietary cell preconditioning technology and its approach to manufacturing an off-the-shelf, allogeneic therapy. Hx-001 is designed to combine multiple therapeutic activities, including reducing inflammation and supporting liver repair, with the potential manufacturing and distribution advantages of a standardized, cryopreserved product.

We believe this combination creates a distinct opportunity within the emerging liver regeneration field.


What intellectual property protects HepaTx's technology, and how defensible is its competitive position?

HepaTx's intellectual property strategy builds on technology originally developed at Stanford University, alongside additional inventions and proprietary methods developed through the company's research and development.

Our portfolio includes licensed intellectual property, patent applications covering cell manufacturing and therapeutic compositions, and additional intellectual property associated with our broader technology platform, including transplant monitoring.

The objective is to protect not just the underlying technology, but important aspects of how therapeutic cells are produced, conditioned, and used to address liver disease.

Beyond patents, our proprietary manufacturing processes, accumulated technical knowledge, preclinical evidence, and development collaborations may create additional barriers to replication.

Investment FAQs

How could HepaTx create value for investors, and what are the potential exit opportunities?

HepaTx's strategy is to build value by advancing its technology through defined development milestones, particularly regulatory progress and the generation of human clinical evidence.

Positive clinical results could increase strategic interest from pharmaceutical companies, biotechnology companies, and potential development partners.

Possible future outcomes include licensing transactions, strategic partnerships, acquisition, or an eventual public offering.

Why invest at this stage rather than waiting until Hx-001 has human clinical results?

HepaTx is approaching a potentially important transition from preclinical research toward human testing. The company has developed its core technology, generated preclinical evidence, established research collaborations, and outlined a path toward an Investigational New Drug (IND) submission.

For early-stage investors, participating before clinical validation offers exposure to potential value creation if the company successfully reaches subsequent technical, regulatory, and clinical milestones.

What will this financing accomplish, and how much more capital will HepaTx need?

The current $1.2 million fundraising plan supports manufacturing readiness, IND-enabling studies, and clinical preparation, with an IND targeted for 2028 and initial human testing planned for 2028/2029.

These milestones are intended to advance Hx-001 toward clinical validation and strengthen the foundation for subsequent investment and potential strategic partnerships.

Additional financing will be required as the program progresses.

We have outlined a potential expanded $5 million financing strategy, with an estimated aggregate $15 million needed to reach an initial Phase I/IIa efficacy readout through a combination of equity financing and potential non-dilutive funding. The scope, timing, and milestones associated with an expanded financing plan remain subject to confirmation.

Why does HepaTx's balance sheet show approximately $5.2 million in liabilities?

The largest component, approximately $3.93 million, represents future-equity obligations associated with previously issued SAFEs. Other liabilities include convertible notes, accrued interest, accounts payable, and related-party loans.

The company reports no conventional senior bank debt or venture debt requiring recurring cash debt service.

While the balance-sheet total includes obligations that are not equivalent to conventional bank loans, existing convertible instruments and other financing obligations can affect future ownership dilution and the company's financial position.


Disclaimer: Certain information set forth on this page contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws. These are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance. All investments involve risk, including the potential loss of capital. HepaTx products presented are not approved by regulatory authorities in any markets and the statements in this presentation represent human testing intent and are not product claims.



Overview